SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose Nearly 10% Stake in Brainstorm Cell Therapeutics
Beneficial Ownership Disclosure
Investment firm Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Brainstorm Cell Therapeutics Inc., held for investment purposes.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
- The Reporting Persons beneficially own 717,500 shares of Common Stock of Brainstorm Cell Therapeutics Inc.
- This ownership represents 9.99% of the total outstanding Common Stock of Brainstorm Cell Therapeutics Inc.
- Both Armistice Capital, LLC and Steven Boyd hold shared voting power and shared dispositive power over all 717,500 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of passive beneficial ownership, indicating a significant but non-controlling stake, which is generally neutral in sentiment. The large stake could be seen as a positive signal by some investors.
Positives
- A significant stake (9.99%) by an institutional investor like Armistice Capital, LLC and its managing member Steven Boyd can be interpreted as a vote of confidence in Brainstorm Cell Therapeutics Inc.'s future prospects.
- The filing explicitly states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment approach.
Risks
- The document itself does not detail specific risks related to Brainstorm Cell Therapeutics Inc.'s operations or financial health, as it is a beneficial ownership disclosure.
Future Outlook
The Schedule 13G filing does not contain any forward-looking statements or guidance regarding Brainstorm Cell Therapeutics Inc.'s future outlook.
Industry Context
This filing indicates a significant investment by a specialized investment firm in Brainstorm Cell Therapeutics, a company operating in the biotechnology sector. Such an investment could reflect a positive view on the company's specific therapeutic pipeline or the broader growth potential within the biotech industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence in the company.
- Company Management: Becomes aware of a large, passive shareholder, which may influence investor relations strategies.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement, indicating the ownership percentage as of this date. |
| 05/15/2025 | Date the Schedule 13G was signed and filed with the SEC. |
Keywords
Brainstorm Cell Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, investment adviser, biotechnology, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.